Clinical Gastroenterology and Hepatology最新文献

{"title":"Altered cognition and patient-reported outcomes predict 1-year hospitalization risk in a multi-center outpatient cirrhosis cohort","authors":"Jasmohan S. Bajaj,Jacqueline G. O’Leary,Jennifer C. Lai,Puneeta Tandon,Florence Wong,Guadalupe Garcia-Tsao,Scott W. Biggins,Philip Vutien,Hugo E. Vargas,Patrick S. Kamath,Jawaid Shaw,Tahira Shaikh,Stefanie Tsai,Dorothea Kent,Daniela Goyes,Brian J. Bush,Scott Silvey,K.Rajender Reddy","doi":"10.1016/j.cgh.2026.09.025","DOIUrl":"https://doi.org/10.1016/j.cgh.2026.09.025","url":null,"abstract":"","PeriodicalId":10347,"journal":{"name":"Clinical Gastroenterology and Hepatology","volume":"18 1","pages":""},"PeriodicalIF":12.6,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149049126","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Data Deluge: Balancing Information Overload and Evidence-Based Medicine in Gastroenterology Fellowship","authors":"Siobhan Proksell,Frank I. Scott","doi":"10.1016/j.cgh.2026.08.018","DOIUrl":"https://doi.org/10.1016/j.cgh.2026.08.018","url":null,"abstract":"","PeriodicalId":10347,"journal":{"name":"Clinical Gastroenterology and Hepatology","volume":"13 1","pages":""},"PeriodicalIF":12.6,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149020288","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness of Medical-Behavioral Therapy in Patients with Fecal Incontinence","authors":"Muhammad Abdul Rehman,Steven Heymen,Satish S.C. Rao,William D. Chey,William E. Whitehead,Isuzu Meyer,Marie G. Gantz,Holly E. Richter,Stacy B. Menees,Nicholas R. Oblizajek,Lawrence A. Szarka,Jan Busby-Whitehead,Kent R. Bailey,Frank A. Hamilton,Adil E. Bharucha","doi":"10.1016/j.cgh.2026.09.024","DOIUrl":"https://doi.org/10.1016/j.cgh.2026.09.024","url":null,"abstract":"","PeriodicalId":10347,"journal":{"name":"Clinical Gastroenterology and Hepatology","volume":"5 1","pages":""},"PeriodicalIF":12.6,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149049128","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gastric and Duodenal Cancer in Lynch Syndrome: Incidence and Endoscopic Surveillance—Systematic Review and Meta-analysis","authors":"Víctor Ausina-Poüs,Sandra Baile-Maxía,María Sáez-Rico,Noelia Sala-Miquel,Carolina Mangas-Sanjuan,Irene Martínez-Tévar,Carmen Sánchez-Ardila,Pedro Zapater,Giulia-Martina Cavestro,Alessandro Mannucci,Zohar Levi,Gregory Idos,Carol A. Burke,Rodrigo Jover","doi":"10.1016/j.cgh.2026.09.027","DOIUrl":"https://doi.org/10.1016/j.cgh.2026.09.027","url":null,"abstract":"","PeriodicalId":10347,"journal":{"name":"Clinical Gastroenterology and Hepatology","volume":"17 1","pages":""},"PeriodicalIF":12.6,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149049127","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Serious Infections in Patients With Inflammatory Bowel Disease and Corticosteroids: A Propensity Score-Matched Study.","authors":"Anders Forss, Jordan Axelrad, Jonas Söderling, Karl Mårild, Olof Grip, Johann P Hreinsson, Jonas Halfvarson, Pontus Naucler, Jonas F Ludvigsson, Ola Olén","doi":"10.1016/j.cgh.2026.08.019","DOIUrl":"10.1016/j.cgh.2026.08.019","url":null,"abstract":"<p><strong>Background & aims: </strong>Absolute risk estimates of serious infections in inflammatory bowel disease (IBD) across therapies and concomitant corticosteroid treatment are limited. We aimed to assess serious infection risk in patients with IBD receiving different therapies, with or without corticosteroids.</p><p><strong>Methods: </strong>Using nationwide Swedish registers (2007-2024), we compared rates of serious infections in patients with IBD treated with different therapies vs matched population comparators (≤10 per patient), stratified by corticosteroid use. We also performed 1:1 propensity score-matching for direct comparison of infection risk in IBD with or without concomitant corticosteroids exposure across advanced therapies. Incidence rates (IRs) and adjusted hazard ratios (aHRs) with 95% confidence intervals were calculated.</p><p><strong>Results: </strong>We identified 145,125 exposure periods in patients with IBD naïve to immunomodulators and advanced therapies, 82,675 to immunomodulators, and 90,181 to advanced therapies (tumor necrosis factor-α inhibitors with and without immunomodulator, anti-integrins, anti-interleukins, and Janus kinase inhibitors). Across therapies, exposure periods with corticosteroids carried a higher risk of serious infections than periods without, both compared with the general population (IR difference range, 3.6-10.2/100 person-years; aHR range, 4.52-15.86) and in propensity score-matched within therapy group comparisons (IR difference range, 3.9-8.5/100 person-years; aHR, 1.82-3.60). The relative risk was highest in children and increased with cumulative corticosteroid dose.</p><p><strong>Conclusions: </strong>Patients with IBD receiving corticosteroids had significantly higher rates of serious infections compared with those not receiving corticosteroids across therapies, with rate differences across age groups and combinations of treatments. These data will inform infection risk assessment and consideration of individualized infection-prevention strategies.</p>","PeriodicalId":10347,"journal":{"name":"Clinical Gastroenterology and Hepatology","volume":" ","pages":""},"PeriodicalIF":16.2,"publicationDate":"2026-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148849786","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Outcomes After Ustekinumab Biosimilar Switching in Crohn's Disease: The USBIOS-Italian Group for the Study of Inflammatory Bowel Disease Study.","authors":"Davide Giuseppe Ribaldone, Elisa Tribocco, Franco Scaldaferri, Marco Murgiano, Simone Parello, Federica Di Vincenzo, Angelo Del Gaudio, Pierluigi Puca, Daniele Napolitano, Alfredo Papa, Loris Riccardo Lopetuso, Lucrezia Laterza, Cristina Bezzio, Alessandro Armuzzi, Valeria Farinola, Edoardo Vincenzo Savarino, Fabiana Zingone, Brigida Barberio, Luisa Bertin, Alessia Todeschini, Angela Variola, Anna Maria Carvalhas Gabrielli, Francesca Ferretti, Rosanna Cannatelli, Antonietta Gerarda Gravina, Raffaele Pellegrino, Anna Viola, Clara De Francesco, Fabrizio Bossa, Luca Pastorelli, Carla Felice, Gabriele Dragoni, Daniele Canova, Linda Cingolani, Rocco Spagnuolo, Maria Maddalena Terpin, Alessandra Zilli, Ambra Magiotta, Francesco Segatta, Simone Saibeni, Ana Juverdeanu, Marta Vernero, Gian Paolo Caviglia","doi":"10.1016/j.cgh.2026.08.014","DOIUrl":"10.1016/j.cgh.2026.08.014","url":null,"abstract":"<p><strong>Background & aims: </strong>Controlled real-world evidence on nonmedical switching from reference ustekinumab to biosimilars in Crohn's disease (CD) is limited. We compared 6-month outcomes after switching vs continued reference treatment.</p><p><strong>Methods: </strong>In this prospective observational cohort at 18 Italian centers, adults with CD in clinical remission (Harvey-Bradshaw Index <5) and steroid-free for ≥8 months of reference ustekinumab, underwent a procurement-driven switch to 1 of 3 approved biosimilars or continued reference treatment. The expanded clinical success end point required clinical remission without systemic corticosteroids, anti-interleukin12 or 23 discontinuation, inflammatory bowel disease-related hospitalization, or intestinal surgery. The protocol-specified noninferiority margin was -15%.</p><p><strong>Results: </strong>Among 462 patients, 337 switched and 125 continued reference ustekinumab; only 4 (0.9%) received every-4-week dosing. Expanded clinical success occurred in 306 of 332 switched patients (92.2%) and 114 of 123 controls (92.7%; risk difference, -0.5%, 95% confidence interval, -5.9 to 4.9), meeting the noninferiority criterion. Results were consistent for the protocol-defined 3-component composite and after propensity-score weighting. Biosimilar persistence was 93.7%; switch-back occurred in 1.2%. Two adverse events were reported after switching.</p><p><strong>Conclusions: </strong>In clinically stable CD, the observed 6-month effectiveness and safety after procurement-driven ustekinumab biosimilar switching were similar to continued reference treatment. Longer-term studies, particularly in patients receiving every-4-week dosing, are needed.</p>","PeriodicalId":10347,"journal":{"name":"Clinical Gastroenterology and Hepatology","volume":" ","pages":""},"PeriodicalIF":16.2,"publicationDate":"2026-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148839384","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Comparative Evaluation of Fibrosis in Patients With and Without Chronic Pancreatitis Undergoing Pancreatic Surgery.","authors":"Aida A Metri, Mahya Faghih, Elham Afghani, Elizabeth Thompson, Michael Noë, Rifat Mannan, Rita Kalyani, Venkata S Akshintala, Zahra Yousefli, Daniel Warren, Niraj M Desai, Zhaoli Sun, Christi Walsh, Lara Cheesman, Martin A Makary, Ralph H Hruban, Jin He, Atif Zaheer, Dana K Andersen, Vikesh K Singh","doi":"10.1016/j.cgh.2026.08.015","DOIUrl":"10.1016/j.cgh.2026.08.015","url":null,"abstract":"<p><strong>Background & aims: </strong>Fibrosis is considered the gold standard for diagnosing chronic pancreatitis (CP) but has not been systematically studied across a large cohort of patients with and without pancreatitis undergoing different pancreatic surgeries.</p><p><strong>Methods: </strong>Demographic, clinical, and radiologic data for patients undergoing total pancreatectomy with islet autotransplantation for indeterminate CP, recurrent acute pancreatitis (RAP), and definite CP; Whipple/Frey for indeterminate and definite CP; and distal pancreatectomy for serous cystadenoma between 2004 and 2023 were reviewed. Definite and indeterminate CP were defined by M-ANNHEIM criteria; and RAP defined as ≥2 episodes of imaging-documented acute pancreatitis. The Ammann Fibrosis Score (FS) was tabulated for all surgical pathology specimens. Patients with serous cystadenoma were included as controls. Data were summarized as median (interquartile range [IQR]) or number (%).</p><p><strong>Results: </strong>There were 206 patients including 24 controls, 31 with indeterminate CP, 36 with RAP, and 115 with definite CP. The median FS was 0.33 (IQR, 0.2-0.5), 2.8 (IQR, 1-6), 6.5 (IQR, 3.7-8), and 8.5 (IQR, 5.9-11) in controls, indeterminate CP, RAP, and definite CP, respectively. Post hoc Dunn tests with Holm adjustment showed significant differences in total FS across all diagnostic groups, with most component scores also differing significantly between groups. There was no correlation between FS and number of AP episodes; however, patients with genetic or idiopathic RAP with ≥7 episodes of AP had similar FS to genetic or idiopathic CP (P = .08).</p><p><strong>Conclusions: </strong>Fibrosis quantification may provide complementary information to existing clinical, imaging, and functional assessments when evaluating patients across the pancreatitis continuum. Current diagnostic criteria for indeterminate CP are leading to an overdiagnosis of CP if fibrosis remains the criteria standard. Among genetic/idiopathic etiologies, patients with RAP with ≥7 episodes of AP have similar quantities of fibrosis to CP.</p>","PeriodicalId":10347,"journal":{"name":"Clinical Gastroenterology and Hepatology","volume":" ","pages":""},"PeriodicalIF":16.2,"publicationDate":"2026-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148839426","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Low Metabolic Dysfunction-Associated Steatotic Liver Disease Awareness and Missed Screening Opportunities: Results From a United Kingdom Population and Clinician Survey.","authors":"Damien Leith, Paul N Brennan, Ruairi W Lynch, John F Dillon, Christopher J Byrne","doi":"10.1016/j.cgh.2026.07.028","DOIUrl":"10.1016/j.cgh.2026.07.028","url":null,"abstract":"<p><strong>Background & aims: </strong>Metabolic dysfunction-associated steatotic liver disease (MASLD) affects over 30% of adults but remains under-recognized. Guidelines recommend screening in high-risk groups; however, MASLD awareness among patients and health care practitioners (HCPs) remains poor, with gaps in knowledge and implementation persisting. We undertook 2 national surveys to quantify MASLD awareness and knowledge gaps and explore screening practices among HCPs.</p><p><strong>Methods: </strong>This cross-sectional study comprised 2 online surveys of the general population in Scotland and United Kingdom HCPs (primary and secondary care). Surveys assessed recognition of MASLD and associated conditions, factors influencing awareness (including inequalities), and HCP screening practices.</p><p><strong>Results: </strong>In the population survey (n = 2114), 71% of respondents were aware of 'fatty liver disease,' compared with 5% for MASLD, and 38% for nonalcoholic fatty liver disease (P < .001). Respondents at higher risk of MASLD, aged less than 60 years, with higher educational attainment, and of female sex, were more likely to be \"aware\" (all P < .01). Most population respondents (98%) reacted positively to wanting a MASLD diagnosis if present. Among HCPs (n = 158), the awareness of fatty liver disease (100%) and nonalcoholic fatty liver disease (98%) was significantly higher than that of MASLD (57%; P < .001). Only 44% of HCPs reported screening any patients for MASLD. Barriers cited included a lack of familiarity with guidelines, limited access to recommended screening tools, and unclear specialist referral pathways.</p><p><strong>Conclusions: </strong>Improved awareness and guideline adoption are imperative to facilitate earlier MASLD diagnosis and intervention. Our findings suggest targeted education for awareness and equitable public health strategies are still needed to address knowledge and management gaps in the United Kingdom among both the general population and HCPs.</p>","PeriodicalId":10347,"journal":{"name":"Clinical Gastroenterology and Hepatology","volume":" ","pages":""},"PeriodicalIF":16.2,"publicationDate":"2026-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148825835","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Incidence of Esophageal Food Impactions and Risk Factors for Recurrence in a Large, Community-Based Health Care System in Northern California.","authors":"Angela Y Lam, Willa Xie, Mahim Naveed, Janet Song, Nathan M Billett, Omar Bakr, Aaron Oh, Eshandeep S Boparai, Douglas A Stram, Christopher Ma, Jeffrey K Lee","doi":"10.1016/j.cgh.2026.08.012","DOIUrl":"10.1016/j.cgh.2026.08.012","url":null,"abstract":"<p><strong>Background & aims: </strong>Esophageal food bolus impaction (EFBI) is a common gastrointestinal emergency with sparse epidemiologic data. We evaluated the epidemiologic and clinical characteristics of EFBI and risk factors for recurrence in a large, community-based, integrated health care organization.</p><p><strong>Methods: </strong>This was a retrospective study of adults with an emergency department (ED) visit for EFBI between 2010 and 2024. Patients with EFBI confirmed on endoscopy were identified for subgroup analysis. The annual incidence rates were assessed, and trends were evaluated using Poisson regression. We characterized patient demographics, endoscopic utilization, and associated diagnoses. We evaluated EFBI recurrence rates and potential risk factors for recurrence utilizing time-to-event survival analysis and multivariable Cox proportional hazards model.</p><p><strong>Results: </strong>A total of 10,146 ED encounters for EFBI among 8231 unique patients were included, and 3431 patients had an endoscopy confirming EFBI. The annual incidence rates fluctuated from 14.79 (95% confidence interval, 13.55-16.12) to 21.52 (95% confidence interval, 19.90-23.24) per 100,000 during the study period, with an initial rise from 2010 to 2016 followed by a decline from 2016 to 2024. The proportion of patients requiring endoscopy declined from 52.7% (2010-2014) to 42.3% (2021-2014), as did the incidence of endoscopically confirmed EFBI (8.12-6.11 per 100,000 from 2010 to 2024, respectively). The highest 5-year cumulative incidences of recurrence were observed in patients with esophageal malignancy (33.7%), eosinophilic esophagitis (24.0%), and esophageal stricture (23.4%).</p><p><strong>Conclusions: </strong>No sustained trends in EFBI incidence were observed from 2010 to 2024, although the proportion of patients requiring endoscopy slightly declined. Eosinophilic esophagitis and benign esophageal stricture were the most common esophageal diagnoses conferring high disease-specific recurrence rates, underscoring an opportunity to optimize diagnosis and treatment.</p>","PeriodicalId":10347,"journal":{"name":"Clinical Gastroenterology and Hepatology","volume":" ","pages":""},"PeriodicalIF":16.2,"publicationDate":"2026-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148811799","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Detection of Potential Metabolic and Alcohol-Associated Liver Disease and Alcohol-Associated Liver Disease Using Phosphatidylethanol in a Large Multicenter Metabolic Dysfunction-Associated Steatohepatitis Trial Screening Cohort.","authors":"Mazen Noureddin, Jörn M Schattenberg, Rashmee Patil, Elizabeth W Brombosz, Gražina Binkauskiene, Michelle Mazuranic, Laura Ladron de Guevara Cetina, Marcelo Kugelmas, Aasim Sheikh, John Poulos, Sudha Kodali, Brian P Lee, Juan Pablo Arab, Naim Alkhouri","doi":"10.1016/j.cgh.2026.08.011","DOIUrl":"10.1016/j.cgh.2026.08.011","url":null,"abstract":"<p><strong>Background & aims: </strong>Accurate distinction between metabolic dysfunction-associated steatotic liver disease (MASLD), alcohol-associated liver disease (ALD), and the overlap metabolic and alcohol-associated liver disease (MetALD) is of utmost importance. Due to the potential for underreporting in alcohol use surveys, phosphatidylethanol (PEth) is increasingly utilized in clinical trials to rule out MetALD or ALD. This study examines the prevalence of elevated PEth and its effectiveness in separating phenotypes with dominant MASLD, MetALD, or ALD in the clinical trial setting.</p><p><strong>Methods: </strong>A multicenter database of patients screened for enrollment in clinical trials for MASLD pharmacologic therapies was reviewed, from which patients with PEth results were identified, then further stratified into low (<20 ng/mL), moderate (20-<100 ng/mL), or high (≥100 ng/mL) alcohol intake groups.</p><p><strong>Results: </strong>Among 2870 patients with baseline PEth data, 2560 (89%) had low, 168 (6%) had moderate, and 142 (5%) had high PEth levels, including 92 with PEth ≥200 ng/mL. Higher hemoglobin A1C was associated with lower PEth (P < .001). Aspartate aminotransferase (P < .001), alanine aminotransferase (P < .001), and γ-glutamyltransferase (P < .001) were elevated in patients with higher PEth results. Indeterminate Fibrosis-4 scores were more prevalent in patients with PEth ≥100 ng/mL (P < .001). In multivariable analysis, PEth ≥20 ng/mL was associated with higher γ-glutamyltransferase (per 10 U/L; adjusted odds ratio, 1.04; 95% confidence interval, 1.03-1.06; P < .001), and lower hemoglobin A1C (adjusted odds ratio, 0.68; 95% confidence interval, 0.60-0.78; P < .001).</p><p><strong>Conclusions: </strong>In this prospective multicenter cohort of participants screened for MASLD clinical trials with systematically collected PEth, 11% had PEth ≥20 ng/mL, suggesting a level of alcohol consumption that may warrant further clinical evaluation for possible MetALD or ALD.</p>","PeriodicalId":10347,"journal":{"name":"Clinical Gastroenterology and Hepatology","volume":" ","pages":""},"PeriodicalIF":16.2,"publicationDate":"2026-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148817772","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}